I Love Melbourne schreef op 21 april 2016 06:58:
Daarnet voor het eerst mij aangemeld op het interessanten IEX forum.
In plaats van alleen maar mee te lezen, wil ik graag onderstaande info met jullie delen:
Zacks Investment Research downgraded shares of Galapagos NV (NASDAQ:GLPG) from a hold rating to a sell rating in a report issued on Friday, Market Beat Ratings reports.
According to Zacks, “Galapagos NV is a biotechnology company. The Company’s operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. “
A number of other brokerages have also recently issued reports on GLPG. Bryan, Garnier & Co raised their price objective on shares of Galapagos NV from $52.00 to $64.00 and gave the company a buy rating in a research note on Thursday, December 17th. Goldman Sachs cut shares of Galapagos NV from a buy rating to a neutral rating in a research note on Monday, January 25th. Cowen and Company reaffirmed a buy rating on shares of Galapagos NV in a research note on Sunday, March 6th. Finally, Morgan Stanley raised their price objective on shares of Galapagos NV from $89.00 to $92.00 in a research note on Friday, April 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. Galapagos NV presently has a consensus rating of Buy and an average price target of $67.20.
Several large investors recently modified their holdings of GLPG. Morgan Stanley raised its stake in shares of Galapagos NV by 38.0% in the fourth quarter. Morgan Stanley now owns 112,640 shares of the company’s stock worth $7,083,000 after buying an additional 31,019 shares during the last quarter. Alps Advisors Inc. bought a new stake in shares of Galapagos NV during the fourth quarter worth approximately $3,232,000. Geduld E E bought a new stake in shares of Galapagos NV during the fourth quarter worth approximately $692,000. Clough Capital Partners L P bought a new stake in shares of Galapagos NV during the fourth quarter worth approximately $7,910,000. Finally, GLG Partners LP raised its stake in shares of Galapagos NV by 501.8% in the fourth quarter. GLG Partners LP now owns 70,309 shares of the company’s stock worth $4,421,000 after buying an additional 58,625 shares during the last quarter.
Shares of Galapagos NV (NASDAQ:GLPG) traded down 1.88% during midday trading on Friday, reaching $43.37. The company’s stock had a trading volume of 5,447 shares. Galapagos NV has a 52 week low of $37.03 and a 52 week high of $65.70. The firm’s market capitalization is $1.69 billion. The firm’s 50 day moving average is $43.31 and its 200 day moving average is $48.43.
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (NASDAQ:GLPG) and Services. The R & D division is engaged in the discovery and development of small molecules.
BRON:
sleekmoney.com/galapagos-nv-glpg-down...